Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Arnold M, Laversanne M, Brown LM, et al. Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am J Gastroenterol. 2017;112(8):1247–1255.
   PubMed Web of Science ®Google Scholar
• Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl. 5):v50–v57.
   PubMed Web of Science ®Google Scholar
• Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(7):855–883.
   PubMed Web of Science ®Google Scholar
• Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992;16(6):1104–1109.
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084.
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–668.
   PubMed Web of Science ®Google Scholar
• Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098.
   PubMed Web of Science ®Google Scholar
• Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experience. Cancer. 2017;123(21):4106–4113.
   PubMed Web of Science ®Google Scholar
• Chao YK, Chen HS, Wang BY, et al. Factors associated with survival in patients with oesophageal cancer who achieve pathological complete response after chemoradiotherapy: a nationwide population-based study. Eur J Cardiothorac Surg. 2017;51(1):155–159.
   PubMed Web of Science ®Google Scholar
• Francoual J, Lebreton G, Bazille C, et al. Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study. J Visc Surg. 2018;155(5):365–374.
   PubMed Web of Science ®Google Scholar
• Al-Sukhni E, Gabriel E, Attwood K, et al. No survival difference with neoadjuvant chemoradiotherapy compared with chemotherapy in resectable esophageal and gastroesophageal junction adenocarcinoma: results from the National Cancer Data Base. J Am Coll Surg. 2016;223(6):784–792e1.
   PubMed Web of Science ®Google Scholar
• van der Werf LR, Dikken JL, van der Willik EM, et al. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: a nationwide study. Eur J Cancer. 2018;91:76–85.
   PubMed Web of Science ®Google Scholar
• Groth SS, Burt BM, Farjah F, et al. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2019;157(4):1682–1693.e1.
   PubMed Web of Science ®Google Scholar
• Lee A, Wong AT, Schwartz D, et al. Is there a benefit to prolonging the interval between neoadjuvant chemoradiation and esophagectomy in esophageal cancer? Ann Thorac Surg. 2016;102(2):433–438.
   PubMed Web of Science ®Google Scholar
• Azab B, Amundson JR, Picado O, et al. Impact of chemoradiation-to-surgery interval on pathological complete response and short- and long-term overall survival in esophageal cancer patients. Ann Surg Oncol. 2019;26(3):861–868.
   PubMed Web of Science ®Google Scholar
• Klevebro F, Lindblad M, Johansson J, et al. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry. Br J Surg. 2016;103(13):1864–1873.
   PubMed Web of Science ®Google Scholar
• Luc G, Gronnier C, Lebreton G, et al. Predictive factors of recurrence in patients with pathological complete response after esophagectomy following neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter study. Ann Surg Oncol. 2015;22(S3):1357–1364.
   Web of Science ®Google Scholar
• Vallbohmer D, Holscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252(5):744–749.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang J, Ding M, et al. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 2018;20(5):570–575.
   PubMed Web of Science ®Google Scholar
• Huang JX, Yan W, Song ZX, et al. Relationship between proliferative activity of cancer cells and clinicopathological factors in patients with esophageal squamous cell carcinoma. World J Gastroenterol. 2005;11(19):2956–2959.
   PubMed Web of Science ®Google Scholar
• Auditing DIfC. Factsheet indicatoren Slokdarm-en maagcarcinoom (DUCA); 2019; [cited 2019 Mar 1]. Available from: https://dica.nl/duca/documenten
   Google Scholar
• Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337(17):1188–1194.
   PubMed Web of Science ®Google Scholar
• Komukai S, Nishimaki T, Suzuki T, et al. Significance of immunohistochemical nodal micrometastasis as a prognostic indicator in potentially curable oesophageal carcinoma. Br J Surg. 2002;89(2):213–219.
   PubMed Web of Science ®Google Scholar
• Vazquez-Sequeiros E, Wang L, Burgart L, et al. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology. 2002;122(7):1815–1821.
   PubMed Web of Science ®Google Scholar
• Heeren PA, Kelder W, Blondeel I, et al. Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. Eur J Surg Oncol. 2005;31(3):270–276.
   PubMed Web of Science ®Google Scholar
• Bleaney CW, Barrow M, Hayes S, et al. The relevance and implications of signet-ring cell adenocarcinoma of the oesophagus. J Clin Pathol. 2018;71(3):201–206.
   PubMed Web of Science ®Google Scholar
• Patel VR, Hofstetter WL, Correa AM, et al. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014;98(3):1064–1071.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu X, Gao L, et al. The clinicopathological features and prognosis of signet ring cell carcinoma of the esophagus: a 10-year retrospective study in China. PLoS One. 2017;12(5):e0176637.
   PubMed Web of Science ®Google Scholar
• van Hootegem SJM, Smithers BM, Gotley DC, et al. The impact of signet ring cell differentiation on outcome in patients with esophageal and gastroesophageal junction adenocarcinoma. Ann Surg Oncol. 2019;26(8):2375–2384.
   PubMed Web of Science ®Google Scholar
• Machlowska J, Pucułek M, Sitarz M, et al. State of the art for gastric signet ring cell carcinoma: from classification, prognosis, and genomic characteristics to specified treatments. Cancer Manag Res. 2019;11:2151–2161.
   PubMed Web of Science ®Google Scholar
• Qin Q, Xu H, Liu J, et al. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis. Int J Surg. 2018;59:11–18.
   PubMed Web of Science ®Google Scholar
• Nilsson K, Klevebro F, Rouvelas I, et al. Surgical morbidity and mortality from the multicenter randomized controlled NeoRes II Trial: standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2020;272(5):684–689.
   PubMed Web of Science ®Google Scholar
• Koëter M, van Steenbergen LN, Lemmens VE, et al. Hospital of diagnosis and probability to receive a curative treatment for oesophageal cancer. Eur J Surg Oncol. 2014;40(10):1338–1345.
   PubMed Web of Science ®Google Scholar
• Puetz K, Bollschweiler E, Semrau R, et al. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer – which response grading system best impacts prognostic discrimination? Histopathology. 2019;74(5):731–743.
   PubMed Web of Science ®Google Scholar
• Klevebro F, Tsekrekos A, Low D, et al. Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. Dis Esophagus. 2020;33(6).
   Web of Science ®Google Scholar
• Karamitopoulou E, Thies S, Zlobec I, et al. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. Am J Surg Pathol. 2014;38(11):1551–1556.
   PubMed Web of Science ®Google Scholar
• Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15(10):2894–2902.
   PubMed Web of Science ®Google Scholar
• Tong DK, Law S, Kwong DL, et al. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol. 2010;17(8):2184–2192.
   PubMed Web of Science ®Google Scholar
• Burt BM, Groth SS, Sada YH, et al. Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer. Ann Surg. 2017;266(2):297–304.
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Yopp AC, Polanco PM, et al. Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score-matched analysis. JAMA Oncol. 2018;4(1):31–38.
   PubMed Web of Science ®Google Scholar
• Stroes CI, Schokker S, Creemers A, et al. Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study. J Clin Oncol. 2019;38(5):462–471.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Lockhart AC, Jonker DJ, et al. CheckMate 577: a randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer. J Clin Oncol. 2017;35(4_Suppl.):TPS212.
   Web of Science ®Google Scholar